Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study

被引：0
|
作者：
Michela Del Prete
François-Alexandre Buteau
Jean-Mathieu Beauregard
机构：
[1] Université Laval,Department of Radiology and Nuclear Medicine, and Cancer Research Center
[2] CHU de Québec – Université Laval,Department of Medical Imaging, and Oncology Branch of Research Center
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
Personalized; Peptide receptor radionuclide therapy; Lu-octreotate; Dosimetry; Neuroendocrine tumours;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1490 / 1500
页数：10
相关论文
共 50 条
  • [21] Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma
    Schneider, Julia R.
    Shatzkes, Deborah R.
    Scharf, Stephen C.
    Tham, Tristan M.
    Kulason, Kay O.
    Buteau, Francois-Alexandre
    Del Prete, Michela
    Chakraborty, Shamik
    Anderson, Todd A.
    Asiry, Saeed
    Beauregard, Jean-Mathieu
    Langer, David J.
    Costantino, Peter D.
    Boockvar, John A.
    OPERATIVE NEUROSURGERY, 2018, 15 (06) : E100 - E109
  • [22] 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
    Hofving, Tobias
    Sandblom, Viktor
    Arvidsson, Yvonne
    Shubbar, Emman
    Altiparmak, Gulay
    Swanpalmer, John
    Almobarak, Bilal
    Elf, Anna-Karin
    Johanson, Viktor
    Elias, Erik
    Kristiansson, Erik
    Forssell-Aronsson, Eva
    Nilsson, Ola
    ENDOCRINE-RELATED CANCER, 2019, 26 (04) : 437 - 449
  • [23] Relapse therapy with 177Lu-octreotate: safety assesment of multiple repeated cycles peptide receptor radionuclide therapy
    Yordanova, A.
    Mayer, K.
    Gonzales-Caramona, M. A.
    Essler, M.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S419 - S420
  • [24] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
    Claringbold, Phillip G.
    Brayshaw, Paul A.
    Price, Richard A.
    Turner, J. Harvey
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (02) : 302 - 311
  • [25] Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
    Phillip G. Claringbold
    Paul A. Brayshaw
    Richard A. Price
    J. Harvey Turner
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 302 - 311
  • [26] Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma COMMENT
    Aghi, Manish
    OPERATIVE NEUROSURGERY, 2018, 15 (06) : E109 - E109
  • [27] Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.
    Bodei, Lisa
    Kidd, Mark S.
    Singh, Aviral
    van der Zwan, Wouter A.
    Severi, Stefano
    Drozdov, Ignat
    Cwikla, Jaroslaw B.
    Baum, Richard P.
    Kwekkeboom, Dik J.
    Paganelli, Giovanni
    Krenning, Eric
    Modlin, Irvin Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
    Sabet, Amir
    Haslerud, Torjan
    Pape, Ulrich-Frank
    Sabet, Amin
    Ahmadzadehfar, Hojjat
    Gruenwald, Frank
    Guhlke, Stefan
    Biersack, Hans-Juergen
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (02) : 205 - 210
  • [29] Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
    Amir Sabet
    Khaled Ezziddin
    Ulrich-Frank Pape
    Karl Reichman
    Torjan Haslerud
    Hojjat Ahmadzadehfar
    Hans-Jürgen Biersack
    James Nagarajah
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 505 - 510
  • [30] Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
    Sabet, Amir
    Ezziddin, Khaled
    Pape, Ulrich-Frank
    Reichman, Karl
    Haslerud, Torjan
    Ahmadzadehfar, Hojjat
    Biersack, Hans-Juergen
    Nagarajah, James
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (03) : 505 - 510
12345